胰臟癌症治疗市场:各癌症类型，各治疗类型，各终端用户，各地区，机会，预测，2017年～2031年

2024-2031年预测期间，全球胰臟癌治疗市场规模将以14.40%的复合年增长率扩大，从2023年的25.2亿美元增至2031年的73.9亿美元。市场成长的推动因素包括胰臟癌患者数量的增加、主要医疗保健公司对研发活动的投资增加以及主要製药公司加强药物开发。胰臟癌盛行率的增加是由多种因素造成的，包括肥胖、饮酒、不健康的生活方式和遗传因素。

全球胰臟癌治疗市场的快速扩张也归因于对治疗胰臟癌的有效治疗方案的需求不断增加、治疗技术的进步以及人们对胰臟癌的认识不断增强。胰臟癌的高死亡率是由于症状检测和晚期诊断有限，迫切需要创新和有效的治疗方法。

此外，领先的公司和製药公司正在大力投资开发潜在的癌症突破性治疗方法，为全球胰臟癌治疗市场创造利润丰厚的成长机会。去年，礼来公司、阿斯特捷利康公司和百时美施贵宝公司在放射性药物合作和研究合作方面花费了约 100 亿美元。製药公司相信，直接向肿瘤提供放射线将是癌症治疗的下一个突破。

放射性药物的工作原理是寻找癌细胞上的特定生物标记物，并将放射性物质附着到附着在其上的目标分子上。同样，2023年12月，诺华公司向中国的放射性製药设施投资约8,500万美元（6亿元）。目前，该公司正在探索新的联合疗法、配体和同位素，不仅针对前列腺癌和胃肠道胰腺神经内分泌肿瘤，还针对肺癌、大肠癌、乳腺癌和胰腺癌。对计划产能扩张的投资预计将加强管道开发，加强现有产品组合，为市场推出做好准备，并加速新疗法的生产。

本报告提供全球胰臟癌症治疗市场相关调查，提供市场概要，以及各癌症类型，各治疗类型，各终端用户，各地区趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 摘要整理

第4章 全球胰臟癌症治疗市场预测，2017年～2031年

• 市场规模的分析与预测
• 市场占有率分析与预测
• 市场地图分析，2023年
  • 各癌症类型
  • 各治疗类型
  • 各终端用户
  • 各地区

第5章 北美的胰臟癌症治疗市场预测，2017年～2031年

第6章 欧洲的胰臟癌症治疗市场预测，2017年～2031年

第7章 亚太地区的胰臟癌症治疗市场预测，2017年～2031年

第8章 南美的胰臟癌症治疗市场预测，2017年～2031年

第9章 中东·非洲的胰臟癌症治疗市场预测，2017年～2031年

第10章 需求供给分析

第11章 价值链分析

第12章 波特的五力分析

第13章 大环境分析

第14章 价格分析

第15章 市场动态

第16章 市场趋势与发展

第17章 法规结构和革新

第18章 专利的形势

第19章 案例研究

第20章 竞争情形

• 前五名市场领导的竞争矩阵
• 前五名参与企业的SWOT分析
• 前10名市场参与企业的形势
  • AstraZeneca PLC
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company Limited

第21章 策略性建议

第22章 咨询方式和免责声明

Global pancreatic cancer treatment market is projected to witness a CAGR of 14.40% during the forecast period 2024-2031, growing from USD 2.52 billion in 2023 to USD 7.39 billion in 2031. The market's growth is bolstered by the rising cases of pancreatic cancer, increasing investments in research and development activities by leading healthcare organizations, and growing drug development efforts by leading pharmaceutical companies. The increasing prevalence of pancreatic cancer can be attributed to various factors, including obesity, alcohol consumption, unhealthy lifestyle, and genetic factors, among others.

The rapid expansion of the global pancreatic cancer treatment market can also be attributed to the rising requirement for effective therapeutic options for managing pancreatic cancer, advancements in treatment technologies, and rising awareness about the condition. The limited symptom detection and late-stage diagnosis of the condition contribute to the high mortality rate of pancreatic cancer, thus creating an urgent requirement for innovative and effective treatments.

Additionally, leading market players and pharmaceutical companies are significantly investing in developing potential cancer breakthroughs, providing lucrative growth opportunities to the global pancreatic cancer treatment market. Over the past year, Eli Lilly and Company, AstraZeneca PLC, and Bristol-Myers Squibb Company have spent approximately USD 10 billion on radiopharmaceutical partnerships and collaborations. Pharmaceutical companies believe that delivering radiation directly to tumors will be the next breakthrough in cancer treatment. Radiopharmaceuticals work by attaching the targeting molecules that search and attach to specific biomarkers on the cancer cells with the radioactive material. Similarly, in December 2023, Novartis AG invested approximately USD 85 million (600 million yuan) in a radioligand facility in China. Currently, the company is exploring new combination therapies, ligands, and isotopes to look beyond prostate cancer and gastroenteropancreatic neuroendocrine tumors and into lung, colon, breast, and pancreatic cancer. The investment towards the planned capacity expansion is expected to bolster pipeline development, strengthen the existing portfolio, prepare for launches, and accelerate the production of novel therapies.

Rising Prevalence of Pancreatic Cancer Boosts Market Demand

The growing burden of the condition in different regions across the globe is one of the major factors bolstering the global pancreatic cancer treatment market demand. With the increasing prevalence of risk factors for pancreatic cancer across the globe, the cases of pancreatic cancer continue to rise, augmenting the requirement for effective therapeutic solutions. As per the estimates of the World Cancer Research Fund International, in 2022, there were more than 510,992 new cases of pancreatic cancer across the globe. Pancreatic cancer has a high mortality rate; because of this, healthcare systems worldwide are focusing on addressing the condition, and the development of effective therapeutic solutions for the disease is becoming a priority.

Increasing Investments in Research Activities Support Market Expansion

The rising investments in research activities in different research institutions across the globe to support the development of therapies for treating pancreatic cancer are expected to influence the market's expansion positively. Investments towards research and development activities are rapidly increasing to address the unmet requirements of pancreatic cancer, with a wide range of research organizations focusing on combination treatments and innovative therapies. Additionally, a significant increase in explore clinical trials exploring new drug candidates with the potential to improve patient outcomes, including immunotherapies and targeted therapies, are being witnessed, further supporting the market's expansion. Moreover, various non-profit and government organizations are also actively funding new therapies for pancreatic cancer. In May 2024, Walter and Eliza Hall Institute of Medical Research received a USD 8 million investment to create a dedicated research center and spearhead new treatments for pancreatic cancer in Australia. The Hemstritch Centre of Excellence for Pancreatic Cancer Research will provide a leading team of clinicians and scientists with funding to make progress in pancreatic cancer treatments, considered the second deadliest cancer in Australia. Such investments are expected to support the development of the next generation of therapies and provide lucrative growth opportunities for the market.

Chemotherapy Accounts for Significant Market Share

The growth of the segment can be attributed to the rising cases of pancreatic cancer, as chemotherapy is used as the first line of treatment for the condition. Cases of pancreatic cancer are usually diagnosed at an advanced stage, where treatments are limited, and chemotherapy is the primary treatment option available for the management of symptoms and controlling the progression of the disease. Although pancreatic cancer is often unresponsive to various treatments, several chemotherapies have been shown to prolong survival and slow down disease progression.

In September 2024, Silexion Therapeutics announced the results from the phase 2 PROTACT trial (NCT01676259). The trial showed that adding siG12D LODER to the standard-of-care chemotherapy improved overall survival and generated responses compared to chemotherapy alone in patients with KRAS G12D/V mutations.

Meanwhile, radiation therapy is expected to grow significantly over the forecast period. In August 2023, researchers from the University of Texas MD Anderson Cancer Center published their multicenter EXTEND trial findings. The results demonstrated that the addition of metastasis-directed radiation therapy to standard chemotherapy improves progression-free survival in patients suffering from oligometastatic pancreatic cancer. The addition of targeted radiation therapy increased the average progression-free survival by four times, showcasing the paradigm-shifting approach of the treatment for metastatic pancreatic cancer.

North America Holds Major Market Share of the Global Market

The rising cases of pancreatic cancer in the region, coupled with the strong presence of leading pharmaceutical companies and robust healthcare infrastructure, are propelling the growth of the North American pancreatic cancer treatment market. As per the estimates of the American Cancer Society, approximately 66,440 cases of pancreatic cancer are projected to be diagnosed in the United States in 2024. Additionally, the availability of government health insurance such as Medicaid and Medicare for qualifying individuals in the country increases the accessibility of the patient population suffering from chronic conditions, including pancreatic cancer, to various treatment options, further bolstering the market's demand in the region. Moreover, the presence of various organizations, such as the National Pancreatic Cancer Foundation (NPCF), that provide information to patients about medical providers and hospitals in their area along with additional assistance, including counseling, are also supporting the market's expansion. Furthermore, the easy availability of novel therapies and the high acceptance of novel treatment technologies in countries such as Canada and the United States are also positively influencing the expansion of the pancreatic cancer treatment market in the region.

Future Market Scenario (2024-2031F)

As per the global pancreatic cancer treatment market analysis, the market is expected to witness significant growth over the forecast period owing to the rising cases of pancreatic cancer and increasing investments by leading pharmaceutical companies toward the development and production of developing and producing novel therapeutic agents. As per the estimates of an article published in the World Journal of Gastroenterology, in 2050, pancreatic cancer incidences are estimated to increase to 18.6 per 100,000.

The major MedTech and biotech companies are also developing advanced diagnostic solutions to allow early-stage detection of pancreatic cancer, further augmenting the requirement for pancreatic cancer treatments. Advancements in immunotherapy, increasing research and development activities, and growing preference for targeted therapies are also expected to shape the market's landscape. Meanwhile, leading pharmaceutical companies across the globe are continuously working on assessing the safety and efficacy of a wide range of therapies for treating pancreatic cancer. For instance, Ono Pharmaceutical Co., Ltd. is conducting an interventional study to investigate the safety and tolerability of ONO-4538 and ONO-7913 in combination with modified FOLFIRINOX as a first-line treatment for metastatic pancreatic cancer. The study is expected to conclude in May 2025.

Key Players Landscape and Outlook

The key players in the market are actively investing in mergers and acquisitions to advance the development of pharmaceuticals for treating various cancer types. In May 2024, Mariana Oncology, Inc. (Mariana Oncology), a biotechnology company focusing on the innovation of radiopharmaceuticals for treating cancer patients, announced that they have been acquired by Novartis AG (Novartis) for up to USD 750 million in potential milestone payments and USD 1 billion upfront. This acquisition brings together Novartis's commercialization expertise and Mariana Oncology's innovative radiopharmaceutical pipeline, aiding the companies in transforming cancer care. This acquisition is also expected to provide Novartis with new capabilities in radioligand therapeutic research and complement their internal drug discovery and research efforts.

The leading market players are also working on introducing novel drugs for addressing the growing threat of pancreatic cancer. The continuous efforts of pharmaceutical companies across the globe to bolster the availability of treatment options for patients with pancreatic cancer are also supporting the market's expansion, with various drugs receiving approvals from different regulatory bodies. In February 2024, Ipsen Biopharmaceuticals, Inc.'s irinotecan liposome (Onivyde) with leucovorin, oxaliplatin, and fluorouracil was approved by the FDA as first-line treatment for metastatic pancreatic adenocarcinoma. The approval was supported by the results of NAPOLI 3, an open-label, randomized, active-controlled, and multicenter trial.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Pancreatic Cancer Treatment Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Cancer Type
    • 4.2.1.1. Endocrine Pancreatic Cancer
    • 4.2.1.2. Exocrine Pancreatic Cancer
  • 4.2.2. By Treatment Type
    • 4.2.2.1. Chemotherapy
    • 4.2.2.2. Radiation Therapy
    • 4.2.2.3. Targeted Therapy
    • 4.2.2.4. Immunotherapy
    • 4.2.2.5. Hormone Therapy
    • 4.2.2.6. Others
  • 4.2.3. By End-user
    • 4.2.3.1. Hospitals
    • 4.2.3.2. Clinics
    • 4.2.3.3. Cancer Care Centers
    • 4.2.3.4. Others
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia-Pacific
    • 4.2.4.4. South America
    • 4.2.4.5. Middle East and Africa
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Cancer Type
  • 4.3.2. By Treatment Type
  • 4.3.3. By End-user
  • 4.3.4. By Region

5. North America Pancreatic Cancer Treatment Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Cancer Type
    • 5.2.1.1. Endocrine Pancreatic Cancer
    • 5.2.1.2. Exocrine Pancreatic Cancer
  • 5.2.2. By Treatment Type
    • 5.2.2.1. Chemotherapy
    • 5.2.2.2. Radiation Therapy
    • 5.2.2.3. Targeted Therapy
    • 5.2.2.4. Immunotherapy
    • 5.2.2.5. Hormone Therapy
    • 5.2.2.6. Others
  • 5.2.3. By End-user
    • 5.2.3.1. Hospitals
    • 5.2.3.2. Clinics
    • 5.2.3.3. Cancer Care Centers
    • 5.2.3.4. Others
  • 5.2.4. By Country Share
    • 5.2.4.1. United States
    • 5.2.4.2. Canada
    • 5.2.4.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Pancreatic Cancer Treatment Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Cancer Type
        • 5.3.1.2.1.1. Endocrine Pancreatic Cancer
        • 5.3.1.2.1.2. Exocrine Pancreatic Cancer
      • 5.3.1.2.2. By Treatment Type
        • 5.3.1.2.2.1. Chemotherapy
        • 5.3.1.2.2.2. Radiation Therapy
        • 5.3.1.2.2.3. Targeted Therapy
        • 5.3.1.2.2.4. Immunotherapy
        • 5.3.1.2.2.5. Hormone Therapy
        • 5.3.1.2.2.6. Others
      • 5.3.1.2.3. By End-user
        • 5.3.1.2.3.1. Hospitals
        • 5.3.1.2.3.2. Clinics
        • 5.3.1.2.3.3. Cancer Care Centers
        • 5.3.1.2.3.4. Others
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Pancreatic Cancer Treatment Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Pancreatic Cancer Treatment Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Pancreatic Cancer Treatment Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Pancreatic Cancer Treatment Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Clinical Trials
• 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. AstraZeneca PLC
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 20.3.2. Pfizer Inc.
  • 20.3.3. Teva Pharmaceutical Industries Ltd.
  • 20.3.4. Novartis AG
  • 20.3.5. Sanofi S.A.
  • 20.3.6. GlaxoSmithKline plc
  • 20.3.7. Merck & Co., Inc.
  • 20.3.8. Bristol-Myers Squibb Company
  • 20.3.9. Eli Lilly and Company
  • 20.3.10. Takeda Pharmaceutical Company Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 3. Global Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 4. Global Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 5. Global Pancreatic Cancer Treatment Market Share (%), By Region, 2017-2031F
• Figure 6. North America Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 7. North America Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 8. North America Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 9. North America Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 10. North America Pancreatic Cancer Treatment Market Share (%), By Country, 2017-2031F
• Figure 11. United States Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 12. United States Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 13. United States Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 14. United States Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 15. Canada Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 16. Canada Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 17. Canada Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 18. Canada Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 19. Mexico Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 20. Mexico Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 21. Mexico Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 22. Mexico Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 23. Europe Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 24. Europe Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 25. Europe Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 26. Europe Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 27. Europe Pancreatic Cancer Treatment Market Share (%), By Country, 2017-2031F
• Figure 28. Germany Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 29. Germany Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 30. Germany Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 31. Germany Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 32. France Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 33. France Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 34. France Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 35. France Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 36. Italy Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 37. Italy Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 38. Italy Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 39. Italy Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 40. United Kingdom Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 41. United Kingdom Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 42. United Kingdom Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 43. United Kingdom Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 44. Russia Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 45. Russia Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 46. Russia Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 47. Russia Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 48. Netherlands Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 49. Netherlands Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 50. Netherlands Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 51. Netherlands Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 52. Spain Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 53. Spain Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 54. Spain Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 55. Spain Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 56. Turkey Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 57. Turkey Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 58. Turkey Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 59. Turkey Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 60. Poland Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 61. Poland Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 62. Poland Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 63. Poland Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 64. South America Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 65. South America Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 66. South America Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 67. South America Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 68. South America Pancreatic Cancer Treatment Market Share (%), By Country, 2017-2031F
• Figure 69. Brazil Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 70. Brazil Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 71. Brazil Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 72. Brazil Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 73. Argentina Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 74. Argentina Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 75. Argentina Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 76. Argentina Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 77. Asia-Pacific Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 78. Asia-Pacific Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 79. Asia-Pacific Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 80. Asia-Pacific Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 81. Asia-Pacific Pancreatic Cancer Treatment Market Share (%), By Country, 2017-2031F
• Figure 82. India Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 83. India Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 84. India Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 85. India Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 86. China Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 87. China Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 88. China Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 89. China Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 90. Japan Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 91. Japan Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 92. Japan Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 93. Japan Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 94. Australia Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 95. Australia Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 96. Australia Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 97. Australia Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 98. Vietnam Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 99. Vietnam Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 100. Vietnam Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 101. Vietnam Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 102. South Korea Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 103. South Korea Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 104. South Korea Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 105. South Korea Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 106. Indonesia Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 107. Indonesia Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 108. Indonesia Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 109. Indonesia Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 110. Philippines Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 111. Philippines Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 112. Philippines Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 113. Philippines Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 114. Middle East & Africa Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 115. Middle East & Africa Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 116. Middle East & Africa Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 117. Middle East & Africa Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 118. Middle East & Africa Pancreatic Cancer Treatment Market Share (%), By Country, 2017-2031F
• Figure 119. Saudi Arabia Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 120. Saudi Arabia Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 121. Saudi Arabia Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 122. Saudi Arabia Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 123. UAE Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 124. UAE Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 125. UAE Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 126. UAE Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 127. South Africa Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 128. South Africa Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
• Figure 129. South Africa Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 130. South Africa Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
• Figure 131. By Cancer Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 132. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 133. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023